CTR3 Antibody

What is CTRP3 and what antibodies are commonly available for its detection?

CTRP3, also known as C1QTNF3, Complement C1q tumor necrosis factor-related protein 3, Collagenous repeat-containing sequence 26 kDa protein, or Secretory protein CORS26, is a member of the C1q/TNF-related protein family . This protein contains a collagenous domain and plays roles in metabolism, inflammation, and tissue homeostasis. Commercially available antibodies for CTRP3 detection include rabbit polyclonal antibodies that have been validated for multiple applications and extensively cited in scientific literature . These antibodies are typically generated using synthetic peptides corresponding to the human C1QTNF3 sequence as immunogens . The immunogen selection is critical for antibody specificity, and researchers should verify the epitope region when selecting antibodies for specific domains of CTRP3.

What applications are CTRP3 antibodies validated for?

CTRP3 antibodies have been validated for several experimental applications including Western blotting (WB), immunohistochemistry on paraffin-embedded tissues (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF) . According to the available literature, these antibodies have been cited in at least 17 scientific publications, indicating their practical utility in research settings . When planning experiments, researchers should consider that different applications require different antibody concentrations and sample preparation methods. For western blotting, reducing conditions may affect epitope accessibility, while for IHC-P, antigen retrieval methods (heat-induced or enzymatic) significantly impact staining outcomes.

How should species reactivity be considered when selecting CTRP3 antibodies?

Species reactivity is a crucial consideration when selecting CTRP3 antibodies. The available research shows that certain commercial antibodies have been specifically tested and confirmed to react with mouse samples . For other species combinations, researchers should examine sequence homology data. Some antibody suppliers categorize species reactivity into verified working combinations, expected working combinations (based on in-house prediction), predicted working combinations (based on homology), and combinations not recommended . Researchers should request homology data or cross-reactivity information from manufacturers when considering antibodies for untested species or obtain validation data from published literature using the same antibody in their species of interest.

What are the recommended storage and handling conditions for CTRP3 antibodies?

Optimal storage and handling conditions are essential for maintaining antibody functionality and specificity. While specific information for CTRP3 antibodies is not detailed in the search results, general antibody handling principles apply. Most antibodies should be stored at -20°C for long-term storage, with working aliquots kept at 4°C to minimize freeze-thaw cycles. When preparing working solutions, antibodies should be diluted in appropriate buffers containing carrier proteins (typically BSA) to prevent non-specific adsorption to surfaces. For each new lot of antibody, validation experiments should be performed to determine optimal working dilutions for specific applications before proceeding with critical experiments.

What methods are recommended for validating CTRP3 antibody specificity?

Validating antibody specificity is fundamental to generating reliable research data. For CTRP3 antibodies, several validation approaches are recommended: (1) Positive and negative control samples with known CTRP3 expression patterns; (2) Blocking peptide competition assays using the immunizing peptide; (3) Knockdown/knockout verification using siRNA or CRISPR-edited cell lines lacking CTRP3 expression; (4) Comparison with alternative antibody clones targeting different epitopes; and (5) Mass spectrometry validation of immunoprecipitated proteins. When interpreting published research, the validation methods used should be carefully assessed to evaluate confidence in the antibody specificity reported.

How does the structural analysis of antibody CDRs inform CTRP3 antibody development?

The structural analysis of complementarity-determining regions (CDRs) in antibodies provides valuable insights for CTRP3 antibody development. Research on antibody CDR loops reveals that CDRH3 (heavy chain CDR3) shows higher variability in sequence composition and structure than other CDRs . While canonical forms have not been defined for CDRH3, analyses of "kinked" and "extended" conformations at the loop's base region (torso) have been conducted . Understanding these structural patterns can guide the design of antibodies with customized specificity profiles for CTRP3. Researchers investigating CTRP3 should consider that the flexibility and conformational diversity of CDR loops significantly impact antibody-antigen interactions . The pseudo bond angle (τ) and pseudo dihedral angle (α) analyses of CDR loops can provide insights into the structural determinants of antibody specificity and cross-reactivity with CTRP3 variants or related proteins.

What methodological approaches exist for developing antibodies with custom specificity profiles for CTRP3?

Developing antibodies with custom specificity profiles for CTRP3 requires sophisticated computational and experimental approaches. Research indicates that phage display experiments with minimal antibody libraries can be effective, particularly when focusing on varying amino acids in the third complementarity determining region (CDR3) . For CTRP3-specific antibodies, researchers can employ energy function optimization to design sequences that either minimize functions associated with desired ligands (for cross-specific antibodies) or minimize functions for desired ligands while maximizing those for undesired ligands (for highly specific antibodies) . This approach enables the generation of antibodies with predefined binding profiles that can discriminate between CTRP3 and related family members. Implementation requires iterative selection processes with high-throughput sequencing to identify candidates meeting the specified binding criteria.

What considerations should be made when comparing results between polyclonal and monoclonal CTRP3 antibodies?

When comparing results between polyclonal and monoclonal CTRP3 antibodies, several important factors must be considered. Polyclonal antibodies, like the rabbit polyclonal antibody mentioned in the search results , recognize multiple epitopes on the CTRP3 protein, potentially providing higher sensitivity but lower specificity compared to monoclonal antibodies. This distinction becomes crucial when analyzing post-translational modifications, splice variants, or protein complexes involving CTRP3. Researchers should implement parallel validation experiments using both antibody types and consider implementing epitope mapping to understand the binding sites. Additionally, quantitative comparisons should account for differences in binding affinity, which can significantly impact signal intensity across different experimental platforms. The following table summarizes key comparative aspects:

How can computational approaches enhance CTRP3 antibody design and analysis?

Computational approaches offer powerful tools for enhancing CTRP3 antibody design and analysis. Machine learning models that predict binding profiles can be developed by optimizing energy functions associated with specific CTRP3 epitopes . These models can be employed to design novel antibody sequences with predefined binding profiles that are either cross-specific or highly specific . For analyzing existing antibody repertoires, kernel density estimation of sequences in high-dimensional sequence space with background signal subtraction can identify clusters of CDRH3 sequences induced upon antigen exposure . Principal component analysis (PCA) of one-hot-encoded unique sequences can differentiate between distinct antibody populations, as demonstrated in other antibody research . Researchers can implement these computational approaches to predict structural similarities between TCR and antibody CDRs, potentially informing the design of TCR-mimic antibodies for CTRP3 recognition in cellular contexts requiring MHC presentation.

What approaches are recommended for quantitative analysis of CTRP3 using antibody-based methods?

For quantitative analysis of CTRP3, enzyme-linked immunosorbent assay (ELISA) represents a gold standard approach. Commercial sandwich ELISA kits for human C1QTNF3 are available with detection ranges of 4.69-300 ng/mL . When developing custom quantification protocols, researchers should consider establishing standard curves using recombinant CTRP3 proteins and validating measurements against alternative quantification methods. For absolute quantification in complex samples, spike-in experiments with known quantities of recombinant protein are essential to assess matrix effects. When analyzing post-translational modifications or specific CTRP3 isoforms, researchers should combine immunoprecipitation with mass spectrometry or use modification-specific antibodies. For tissue-specific quantification, normalization to appropriate housekeeping proteins is necessary, with selection based on stability across experimental conditions rather than conventional choices.

How do structural differences between TCR and antibody CDRs impact CTRP3-targeted immunotherapy approaches?

Structural differences between T-cell receptor (TCR) and antibody CDRs have significant implications for CTRP3-targeted immunotherapy approaches. Research indicates that TCR loops exhibit greater flexibility than antibody CDRs , and their length distributions differ significantly . When developing immunotherapeutic approaches targeting CTRP3, these structural distinctions influence whether antibody-based or TCR-based strategies are more appropriate. Antibody CDRs tend to have kinked torso structures, while TCR CDRs favor extended conformations . This structural difference impacts the recognition of CTRP3 epitopes, particularly in contexts requiring MHC presentation versus direct protein recognition. For immunotherapy applications, antibody-based approaches might be preferable for secreted CTRP3, while TCR-based approaches could target cells producing CTRP3 through MHC-presented peptides. Understanding the pseudo bond angle (τ) and pseudo dihedral angle (α) profiles characteristic of successful CTRP3-binding molecules can guide rational design of therapeutic agents with optimal structural properties.